LOS ANGELES, CA — On May 29, 2026, attorneys William Marler of Marler Clark, Inc., PS and Trevor Quirk of Quirk Law Firm LLP filed a personal injury lawsuit in Los Angeles County Superior Court on behalf of Samantha Sabaite and her minor child, J.A.K., arising from a confirmed E. coli O157 infection that left J.A.K. hospitalized with hemolytic uremic syndrome (HUS), a life-threatening kidney complication. 

The defendants are TKS Restaurants, LLC, doing business as The Kebab Shop, a restaurant chain operating in California, Texas, and Florida, and Olympia Food Industries, Inc., the Illinois manufacturer that supplied the raw ground beef kofta served at The Kebab Shop locations.

“I have been litigating E. coli cases for thirty-three years, beginning with the 1993 Jack in the Box outbreak,” said attorney William D. Marler. “After decades of improvements in testing and food safety interventions, serious ground beef outbreaks had become increasingly rare. What makes this outbreak alarming is that we are seeing these preventable illnesses return, and once again the victims are disproportionately children.”

“J.A.K. ate a kebab at a restaurant and ended up in intensive care on dialysis with seizures,” Marler added. “That should never happen in 2026.”

The Outbreak

The California Department of Public Health (CDPH), the USDA Food Safety and Inspection Service (FSIS), and local health departments are investigating an outbreak of Shiga toxin-producing E. coli O157 linked to beef kofta sold at The Kebab Shop. As of May 19, 2026, nine California residents had been infected with the outbreak strain, including six children. Five people were hospitalized and two developed HUS.

On May 24, 2026, FSIS issued a public health alert after beef kofta samples collected from The Kebab Shop tested positive for E. coli O157. The Kebab Shop had voluntarily removed beef kofta from all locations on May 18. According to investigators, the contaminated product was manufactured by Olympia Foods on January 6, 2026, and distributed to restaurant locations in California, Texas, and Florida.

The Plaintiff

According to the complaint, J.A.K. consumed beef kofta at The Kebab Shop on Los Feliz Boulevard in Los Angeles on or about April 1, 2026. Two days later, he developed symptoms consistent with E. coli infection, including nausea, vomiting, severe fatigue, and bloody diarrhea. On April 6, his mother brought him to the emergency room.

J.A.K. was admitted to UCLA Santa Monica Hospital, where testing confirmed Shiga toxin-producing E. coli. As his condition deteriorated, he was transferred to the intensive care unit at UCLA Westwood Hospital and diagnosed with HUS. He required dialysis and blood transfusions and suffered seizures and decreased pancreatic function during his hospitalization. Whole genome sequencing linked his illness to the outbreak strain associated with The Kebab Shop beef kofta.

Legal Claims

The lawsuit alleges Strict Product Liability, Breach of Implied Warranty, Negligence, and Negligence Per Se against both defendants. The complaint alleges the defendants failed to manufacture, supply, and serve food safe for human consumption and violated federal food safety laws and USDA performance standards governing ground beef.

E. coli O157:H7 and Ground Beef 

E. coli O157 is a dangerous pathogen commonly associated with contaminated ground beef. The bacteria can cause severe illness, including bloody diarrhea and kidney failure, particularly in young children. Approximately 10 percent of infected individuals – most of them children – develop hemolytic uremic syndrome  (HUS), which can result in permanent kidney damage, neurological injury, or death.

The USDA declared E. coli O157 an adulterant in raw ground beef in 1994 following the Jack in the Box outbreak that sickened more than 700 people and killed four children. Proper cooking of ground beef to an internal temperature of 160°F kills the bacteria.

About Marler Clark 

Marler Clark, Inc., PS is a Seattle-based law firm focused exclusively on representing victims of foodborne illness. The firm has litigated cases arising from virtually every major E. coliSalmonellaListeria, and other food safety outbreak in the United States over the past thirty years. William D. Marler is widely recognized as the nation’s leading food safety attorney. More information is available at www.marlerclark.com and www.billmarler.com

For all media inquires contact Marler Clark at 206-346-1888 or email jdueck@marlerclark.com.

As of May 19, 2026, nine California residents have been infected with the outbreak strain of STEC O157:H7. Illness onset dates range from March 27 through April 30, 2026. Six illnesses are in children. Five individuals have been hospitalized, and two have developed HUS. No deaths have been reported. No individuals from other states are currently linked to this outbreak. 

The California Department of Public Health (CDPH) is advising consumers to be aware of possible exposure to Shiga toxin-producing E. coli (STEC) O157:H7 bacteria from consumption of beef kofta (seasoned ground beef kebabs) served at The Kebab Shop restaurant chain locations in Northern and Southern California. Consumers should call their health care provider if they become sick with symptoms of STEC infection within 10 days of eating this product. 

CDPH is working with local health departments and federal partners to investigate an STEC O157:H7 outbreak linked to the consumption of beef kofta served at several California locations of The Kebab Shop restaurant chain. The Kebab Shop has voluntarily paused sales of grilled beef kofta at all locations. 

Symptoms of STEC infection may include diarrhea (often bloody), vomiting and abdominal cramps. Symptoms usually start three to four days after a person is infected. Most people get better on their own within a week, but some people may develop severe diseases that require hospital care. Young children are at highest risk of getting hemolytic uremic syndrome (HUS), a severe complication that can lead to acute kidney failure.  

As of May 19, 2026, nine California residents have been infected with the outbreak strain of STEC O157:H7. Illness onset dates range from March 27 through April 30, 2026. Six illnesses are in children. Five individuals have been hospitalized, and two have developed HUS. No deaths have been reported. No individuals from other states are currently linked to this outbreak.  

Interviews with ill individuals indicate that grilled beef kofta served at The Kebab Shop is the likely outbreak source. The Kebab Shop is fully cooperating with public health officials and voluntarily paused sales of grilled beef kofta at all locations on May 18.  

The risk of exposure to this product is not ongoing at this time. While the investigation is ongoing, current information suggests the implicated beef product was distributed only to The Kebab Shop. CDPH and partner agencies continue to investigate to identify the cause of the outbreak, monitor for additional ill persons, and conduct product testing.  

William “Bill” Marler has been a food safety lawyer and advocate since the 1993 Jack-in-the-Box E. coli Outbreak which was chronicled in the book, “Poisoned” and in the recent Emmy Award winning Netflix documentary by the same name. Bill work has been profiled in the New Yorker, “A Bug in the System;” the Seattle Times, “30 years after the deadly E. coli outbreak, A Seattle attorney still fights for food safety;” the Washington Post, “He helped make burgers safer, Now he is fighting food poisoning again;” and several others. 

Dozens of times a year Bill speaks to industry and government throughout the United States, Canada, Europe, Africa, China and Australia on why it is important to prevent foodborne illnesses.  He is also a frequent commentator on food litigation and food safety on Marler Blog. Bill is also the publisher of Food Safety News.

E. coli:  Marler Clark, The Food Safety Law Firm, is the nation’s leading law firm representing victims of E. colioutbreaks and hemolytic uremic syndrome (HUS). The E. coli lawyers of Marler Clark have represented thousands of victims of E. coli and other foodborne illness infections and have recovered over $900 million for clients. Marler Clark is the only law firm in the nation with a practice focused exclusively on foodborne illness litigation.  Our E. coli lawyers have litigated E. coli and HUS cases stemming from outbreaks traced to ground beef, raw milk, lettuce, spinach, sprouts, and other food products.  The law firm has brought E. coli lawsuits against such companies as Jack in the Box, Dole, ConAgra, Cargill, and Jimmy John’s.  We have proudly represented such victims as Brianne KinerStephanie Smith and Linda Rivera.

If you or a family member became ill with an E. coli infection or HUS after consuming food and you’re interested in pursuing a legal claim, contact the Marler Clark E. coli attorneys for a free case evaluation.

Additional Resources:

Illnesses have been reported in Alaska, Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Iowa, Idaho, Illinois, Kentucky, Massachusetts, Maine, Michigan, Minnesota, Missouri, North Carolina, North Dakota, Nebraska, New Jersey, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Vermont, Washington and Wisconsin.

The FDA and CDC, in collaboration with state and local partners, reopened a multistate outbreak investigation of Salmonella Typhimurium and Salmonella Newport infections linked to recalled dietary supplements containing imported moringa leaf powder due to the addition of new cases and exposure information.

Since the investigation was closed on March 17, 2026, 22 new illnesses from 4 states have been reported. The investigation has since been reopened, and as of May 27, 2026, a total of 119 people infected with one of the outbreak strains of Salmonella have been reported from 36 states since the investigation began. Whole genome sequencing (WGS) showed that bacteria from sick people’s samples are closely related genetically. Illnesses started on dates ranging from August 22, 2025, to April 26, 2026. Of 109 people with information available, 32 have been hospitalized. No deaths have been reported. 

Of the 79 people interviewed, including some of the 22 new cases, 70 (89%) reported eating a product containing moringa leaf powder, including 60 who reported Live it Up Super Greens supplement powders only, 5 who reported Why Not Natural moringa powder capsules only, 1 person who reported consuming both Live it Up Super Greens supplement powder and Why Not Natural moringa powder capsules, and 4 who reported TNVitamins moringa powder capsules only.

On May 26, 2026, Total Nutrition Inc. of Deer Park, NY, recalled:

  • Tnvitamins-brand Ultra Potent Complete Green Superfood Moringa capsules 10,000 mg (120 capsules) lot 2507199 EXP 09/2027, lot 2512-304 EXP 02/2028, and lot 2793 EXP 02/2028
  • Doctor’s Pride Complete Green Superfood Ultra Potent Moringa 10,000 mg (120 capsules) Lot: 2507199 Exp. 09/2027

All Recalls:

Total Nutrition Inc. Recall

Superfoods, Inc. Recall

Why Not Natural Recall

FDA is conducting additional traceback of the supply chain to identify the source of the outbreak. Additionally, FDA is working with state and local partners to sample products and determine if additional products may be contaminated. FDA will update this advisory with new information as it becomes available. FDA’s investigation is ongoing.


Case Count Map Provided by CDC

CDC case count map with cases in Alabama, California, Connecticut, Delaware, Iowa, Illinois, Kentucky, Massachusetts, Maine, Michigan, Minnesota, Missouri, North Carolina, North Dakota, Nebraska, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Vermont, Washington, Wisconsin

The Live it Up Super Greens recall impacts markets outside the United States. Customer information provided by the firm shows that recalled product was sold to consumers in the United Kingdom. The recalled product was also sold to consumers located nationwide in the United States, including Puerto Rico, Guam, and Virgin Islands.

“Where people typically thought of food safety as this three-legged stool — the consumer groups, the government, and the industry — Bill sort of came in as a fourth leg and actually was able to effect changes in a way that none of the others really had.” Former FDA Official

The Beginning: Jack in the Box, 1993

In January 1993, children started showing up at Western Washington emergency rooms desperately ill — the culprit was undercooked hamburgers from Jack in the Box restaurants. More than 700 people, most under the age of 10, were sickened across five states. Many never fully recovered, and four children died.

Bill Marler, then less than five years out of law school, had never heard of E. coli O157:H7 before the outbreak. He spent hours in the University of Washington medical school library before filing one of the first lawsuits. He ultimately represented Brianne Kiner, the most seriously injured survivor — a nine-year-old who spent 40 days in a coma, and whose doctors didn’t expect her to survive. Marler negotiated a $15.6 million settlement, setting a state record. He and his colleagues won $50 million in damages for nearly 200 victims in total. 

E. coli O157:H7 as an Adulterant

The Jack in the Box outbreak was a watershed moment not just legally but regulatorily. The declaration of E. coli O157:H7 as an adulterant in ground beef was met with strong opposition from the meat industry, which filed suit claiming the USDA had acted arbitrarily. However, the United States District Court upheld the USDA’s authority, finding it had the power to declare substances adulterants to spur the industry to implement preventative measures. That designation meant that any ground beef testing positive for O157:H7 was legally considered adulterated and could not be sold — a powerful enforcement tool.

The Non-O157 Petition

Marler didn’t stop there. Concerned that non-O157 Shiga toxin-producing E. coli strains were sickening Americans but receiving almost no regulatory attention, Marler personally funded a major scientific study costing approximately $500,000, in partnership with microbiologist Dr. Mansour Samadpour of the Seattle-based Institute for Environmental Health. They tested 5,000 large retail packages of ground beef across the country for all strains of E. coli.

The results showed approximately 2% contamination — meaning that given the billions of pounds of ground beef consumed annually, millions of pounds of potentially dangerous meat were reaching consumers every year, and regulators weren’t even required to look for it.

In 2009, Marler Clark petitioned FSIS to extend the adulterant designation to non-O157 Shiga toxin-producing E. coli strains, filing on behalf of three seriously injured victims and documenting the science. FSIS resisted for years. When the agency failed to respond as required by law, Marler threatened to sue — at which point USDA formally acknowledged receipt.

In 2012, FSIS finally acted: six additional non-O157 strains — O26, O45, O103, O111, O121, and O145 — were declared adulterants. The same industry warnings about economic catastrophe followed. And the same thing happened: the system adapted, illnesses declined, and the sky did not fall.

“Put Me Out of Business”

One of Marler’s most memorable contributions to the food safety conversation was a challenge he issued to the beef industry and USDA in an op-ed for the Denver Post. Just over 20 years after writing that op-ed challenging the USDA/FSIS and the beef industry to “put him out of business,” E. coli cases linked to ground beef had nearly, but not completely, disappeared. As Marler put it: “I could count on a significant E. coli outbreak and recall occurring like clockwork nearly every Spring or Summer. When 2003 came, there were no outbreaks. E. coli cases linked to ground beef are no longer a part of the work we do anymore. The industry to its credit did its job and met my challenge.”

From the Jack in the Box outbreak of 1993 until the 2002 ConAgra E. coli outbreak, at least 95% of Marler Clark’s revenue was from E. coli cases linked to hamburger. Today, it is nearly zero.

Even as the broader trend improved, individual tragedies persisted. Stephanie Smith was a 22-year-old dance instructor from Cold Spring, Minnesota, who developed hemolytic uremic syndrome (HUS) after eating a Cargill-produced hamburger contaminated with E. coli O157:H7. She was left paralyzed from the waist down. Stephanie’s story became the subject of a Pulitzer Prize–winning investigation by New York Times reporter Michael Moss, who traced her burger through the entire supply chain and exposed the industry’s practice of blending trim from multiple processors with minimal testing. Marler represented Smith in her lawsuit against Cargill.

The Netflix Documentary

Marler is a featured figure in the Netflix documentary Poisoned: The Dirty Truth About Your Food, which chronicles his decades-long career as a leading food safety advocate and lawyer. The film is based on Jeff Benedict’s book Poisoned, which details Marler’s involvement in the landmark 1993 Jack in the Box E. coli outbreak, including the $15.6 million settlement for Brianne Kiner 

Fewer E. coli Cases Linked to Hamburger

The regulatory and industry reforms that Marler fought for have clearly had an impact. Since the 2018 E. coli outbreak linked to Romaine lettuce from Yuma, E. coli, Salmonella, Listeria, and hepatitis A outbreaks linked to fresh fruits and vegetables now take up the bulk of Marler’s attention — a remarkable shift from the days when ground beef dominated his caseload.

The Kebab Shop Outbreak, 2026

That said, ground beef has not been entirely tamed. Just this month, as of May 19, 2026, nine California residents have been infected with the outbreak strain of STEC O157:H7, with illness onset dates ranging from March 27 through April 30, 2026. Six of the illnesses are in children. Five individuals have been hospitalized, and two have developed HUS. The beef kofta — seasoned ground beef kebabs — was produced by Olympia Food Industries in Franklin Park, Illinois, and supplied to The Kebab Shop restaurant chain locations in California, Texas, and Florida. Leftover ground beef tested positive for E. coli. The Kebab Shop stopped selling beef kofta at all locations on May 18, 2026.

Bill Marler

William “Bill” Marler has been a food safety lawyer and advocate since the 1993 Jack-in-the-Box E. coli Outbreak which was chronicled in the book, “Poisoned” and in the recent Emmy Award winning Netflix documentary by the same name. Bill work has been profiled in the New Yorker, “A Bug in the System;” the Seattle Times, “30 years after the deadly E. coli outbreak, A Seattle attorney still fights for food safety;” the Washington Post, “He helped make burgers safer, Now he is fighting food poisoning again;” and several others. 

Dozens of times a year Bill speaks to industry and government throughout the United States, Canada, Europe, Africa, China and Australia on why it is important to prevent foodborne illnesses.  He is also a frequent commentator on food litigation and food safety on Marler Blog. Bill is also the publisher of Food Safety News.

The CDPH is working with local health departments and federal partners to investigate an STEC O157:H7 outbreak linked to the consumption of beef kofta served at several California locations of The Kebab Shop restaurant chain. The Kebab Shop has voluntarily paused sales of grilled beef kofta at all locations. As of May 19, 2026, nine California residents have been infected with the outbreak strain of STEC O157:H7. Illness onset dates range from March 27 through April 30, 2026. Six illnesses are in children. Five individuals have been hospitalized, and two have developed HUS – acute kidney failure.

Sources, Characteristics, and Identification

Escherichia coli (E. coli) is an archetypal commensal bacterial species that lives in mammalian intestines. E. coliO157:H7 is one of thousands of serotypes E. coli.[1] The combination of letters and numbers in the name of E. coliO157:H7 refers to the specific antigens (proteins which provoke an antibody response) found on the body, as well as on the tail, or flagellum,[2] and distinguish it from other types of E. coli.[3] Most serotypes of E. coli are harmless and live as normal flora in the intestines of healthy humans and animals.[4]

The E. coli bacterium is among the most extensively studied microorganisms.[5] The testing to distinguish E. coli O157:H7 from its other E. coli counterparts is called serotyping.[6] Pulsed-field gel electrophoresis (PFGE),[7]sometimes also referred to as genetic fingerprinting, is used to compare E. coli O157:H7 isolates to one another to determine if the strains are distinguishable.[8] A technique called multilocus variable number of tandem repeats analysis (MLVA) is used to determine precise classification when it is difficult to differentiate between isolates with indistinguishable or very similar PFGE patterns.[9]

E. coli O157:H7 was first recognized as a pathogen in 1982 during an investigation into an outbreak of hemorrhagic colitis[10] associated with consumption of hamburgers from a fast food chain restaurant.[11] Retrospective examination of more than three thousand E. coli cultures obtained between 1973 and 1982 found only one (1) isolationwith serotype O157:H7, and that was a case in 1975.[12] In the ten (10) years that followed there were approximately thirty (30) outbreaks recorded in the United States.[13] This number is likely misleading, however, because E. coliO157:H7 infections did not become a reportable disease in any state until 1987, when Washington became the first state to mandate its reporting to public health authorities.[14] As a result, only the most geographically concentrated outbreak would have garnered enough notice to prompt further investigation.[15]

E. coli O157:H7’s ability to induce injury in humans is a result of its ability to produce numerous virulence factors—most notably, Shiga-like toxins (SLT).[16] Shiga toxin (Stx) has multiple variants (e.g. Stx1, Stx2, Stx2c), and acts like the plant toxin ricin by inhibiting protein synthesis in endothelial and other cells.[17] Shiga toxin is one of the most potent toxins known.[18] In addition to Shiga toxins, E. coli O157:H7 produces numerous other putative virulence factors including proteins, which aid in the attachment and colonization of the bacteria in the intestinal wall and that can lyse red blood cells to liberate iron that helps support E. coli metabolism.[19]

E. coli O157:H7 evolved from enteropathogenic E. coli serotype O55:H7, a cause of non-bloody diarrhea, through the sequential acquisition of phage-encoded Stx2, a large virulence plasmid, and additional chromosomal mutations.[20]The rate of genetic mutation of E. coli O157:H7 indicates that the common ancestor of current E. coli O157:H7 clades[21] likely existed some 20,000 years ago.[22] E. coli O157:H7 is a relentlessly evolving organism[23], constantly mutating and acquiring new characteristics, including virulence factors that make the emergence of more dangerous variants a constant threat.[24] The CDC has emphasized the prospect of emerging pathogens as a significant public health threat for some time.[25]

Although foods of a bovine origin are the most common cause of both outbreaks and sporadic cases of E. coliO157:H7 infections,[26] outbreak of illnesses have been linked to a wide variety of food items. For example, produce has, since 1991, been the source of substantial numbers of outbreak-related E. coli O157:H7 infections.[27] Other unusual vehicles for E. coli O157:H7 outbreaks have included unpasteurized juices, yogurt, dried salami, mayonnaise, raw milk, game meats, sprouts, and raw cookie dough.[28]

According to updated CDC estimates, an estimated 97,000 illnesses are caused by domestically acquired E. coliO157:H7 each year in the United States.[29] It is estimated that STEC O157 infections result in approximately 3,270 hospitalizations and 30 deaths annually in the United States (CDC, Technical Information on E. coli).[30] The colitis caused by E. coli O157:H7 is characterized by severe abdominal cramps, diarrhea that typically turns bloody within twenty-four hours, and sometimes fevers.[31] The incubation period—which is to say the time from exposure to the onset of symptoms—in outbreaks is usually reported as three to four days, but may be as short as one day or as long as ten days.[32] Infection can occur in people of all ages but is most common in children.[33] The duration of an uncomplicated illness can range from one to twelve days.[34] Although the rate of death is 0-2 percent in reported outbreaks, in outbreaks that involve the elderly, like those that have occurred in nursing homes, the rate of death can run as high as 16-35%.[35]

What makes E. coli O157:H7 remarkably dangerous is its very low infectious dose,[36] and how relatively difficult it is to kill the bacteria.[37] Unlike Salmonella, for example, which usually requires something approximating an “egregious food handling error, E. coli O157:H7 in ground beef that is only slightly undercooked can result in infection,”[38] as few as twenty organisms may be sufficient to infect a person and, as a result, possibly kill them.[39] And unlike generic E. coli, the O157:H7 serotype multiplies at temperatures up to 44°F, survives freezing and thawing, is heat resistant, grows at temperatures up to 111°F, resists drying, and can survive exposure to acidic environments.[40] And, finally, to make it even more of a threat, E. coli O157:H7 bacteria are easily transmitted by person-to-person contact.[41]There is also the serious risk of cross-contamination between raw meat and other food items intended to be eaten without cooking. Indeed, a principle and consistent criticism of the USDA E. coli O157:H7 policy is the fact that it has failed to focus on the risks of cross-contamination versus that posed by so-called improper cooking.[42] With this pathogen, there is ultimately no margin of error. It is for this precise reason that the USDA has repeatedly rejected calls from the meat industry to hold consumers primarily responsible for E. coli O157:H7 infections caused, in part, by mistakes in food handling or cooking.[43]

Hemolytic Uremic Syndrome (HUS)

E. coli O157:H7 infections can lead to a severe, life-threatening complication called hemolytic uremic syndrome (“HUS”).[44] HUS accounts for the majority of the acute and chronic illness and death caused by E coli bacteria.[45]HUS occurs in 2-7% of victims who are primarily children, with onset occurring five to ten days after diarrhea begins.[46] HUS is the most common cause of renal failure in children.[47] Approximately half of the children who suffer HUS require dialysis, and at least 5% of those who survive have long-term renal impairment.[48] The same number suffers severe brain damage.[49] While somewhat rare, serious injury to the pancreas, resulting in death or the development of diabetes, can also occur.[50] There is no cure or effective treatment for HUS.[51]  And, tragically, children with HUS too often die.[52]

HUS is believed to develop when SLT from the bacteria enters circulation in the body through the inflamed bowel wall.[53] SLT, and most likely other chemical mediators, attach to receptors on the inside surface of blood vessel cells (endothelial cells) and initiate a chemical cascade that results in the formation of tiny thrombi (blood clots) within these vessels.[54] Some organs seem more susceptible, perhaps due to the presence of increased numbers of receptors, and include the kidney, pancreas, and brain.[55] By definition, when fully expressed, HUS presents with the triad of hemolytic anemia (destruction of red blood cells), thrombocytopenia (low platelet count), and renal failure (loss of kidney function).[56]

As already noted, there is no known therapy to halt the progression of HUS. HUS is a frightening complication that even in the best American medical centers has a notable mortality rate.[57] Among survivors, at least five percent will suffer end stage renal disease (ESRD) with the resultant need for dialysis or transplantation.[58] But “[b]ecause renal failure can progress slowly over decades, the eventual incidence of ESRD cannot yet be determined.”[59] Other long-term problems include the risk for hypertension, proteinuria (abnormal amounts of protein in the urine that can portend a decline in renal function), and reduced kidney filtration rate.[60] Since the longest available follow-up studies of HUS victims are twenty-five years, an accurate lifetime prognosis is not really available and remains controversial.[61] All that can be said for certain is that HUS causes permanent injury, including loss of kidney function, and it requires a lifetime of close medical monitoring.

The Pathophysiology of Acute Hemolytic Uremic Syndrome

Post-diarrheal hemolytic uremic syndrome (D+HUS) is a severe, life-threatening complication that occurs in about 10 percent of those infected with E. coli O157:H7 or other Shiga toxin-producing (Stx) E. coli (STEC).

The cascade of events leading to HUS begins with ingestion of Stx-producing E. coli (e.g., E. coli O157: H7) in contaminated food, beverages, animal to person, or person-to-person transmission. The bacteria rapidly multiply in the gut, causing inflammation and diarrhea (colitis) as they tightly bind to cells that line the large intestine. This snug attachment becomes a route for the toxin to travel from the gut into the bloodstream, where it attaches to weak receptors on white blood cells (WBCs). From there, WBCs carry the toxin to the kidneys and other organs. 

To induce toxicity in target cells, Shiga toxins must first bind to specific receptors on their surface (Gb3 receptors). Organ injury is primarily a function of Gb3 receptor location and density. They are found on epithelial, endothelial, mesangial, and glomerular cells of the kidney, as well as microvascular endothelial cells of the brain and intestine. Because this attachment causes these organs to be susceptible to the toxicity of Shiga toxins, this distribution explains the involvement of the gut, kidney, and brain in STEC-associated hemolytic uremic syndrome (HUS).[62]

Within the target organ, Shiga toxins disrupt the cellular machinery, resulting in cell injury and/or death. Within the intestine, infectious bacterial lesions cause derangements in the intestinal lining, disrupting the structure of the villi, affecting absorption in the gut, and eventually leading to watery diarrhea. Damage to the intestinal endothelium also causes mucosal/submucosal edema and, hemorrhage, introducing blood into the diarrhea.

Within the circulatory system, Shiga toxins are directly involved in platelet activation and aggregation (clot formation). The thrombotic microangiopathy that characterizes hemolytic uremic syndrome (HUS) occurs when platelet microthrombi (tiny clots) form in the walls of small blood vessels (arterioles and capillaries) causing platelet consumption. This pathologic reduction in platelets is called thrombocytopenia and is one of the hallmarks of HUS.[63]Within the microvasculature of the kidney these clots disturb blood flow to the organ, causing acute kidney injury and kidney failure.

How hemolytic uremic syndrome (HUS) causes permanent kidney damage

The kidney is the main target organ in STEC-mediated HUS. The nephron is the functional unit of the kidney. Each kidney contains approximately 1.2 million nephrons. At the heart of each nephron is a microscopic bundle of blood vessels called the glomerulus. The glomerulus represents the initial location of the renal filtration of blood.[64] Blood enters the glomerulus through the afferent arteriole at the vascular pole, undergoes filtration in the glomerular capillaries, and exits the glomerulus through the efferent arteriole at the vascular pole.

Bowman’s capsule surrounds the glomerular capillary loops and participates in the filtration of blood from the glomerular capillaries. Bowman’s capsule also has a structural function and creates a urinary space through which filtrate can enter the nephron and pass to the proximal convoluted tubule. Liquid and solutes of the blood must pass through multiple layers to move from the glomerular capillaries into Bowman’s space to ultimately become filtrate within the nephron’s lumen. This ends the first stage in the production of urine.

In the rare event that the results of renal biopsies are known, microthrombi have been identified in the glomerular capillaries, resulting in extensive endothelial damage and, frequently, death of the nephron.[65] Severe cases develop acute cortical necrosis affecting most cells in the renal cortex. Damage to tubular cells results in electrolyte disturbances, acidosis and decreased urine production. 

As seen in other kidney diseases, in STEC-HUS patients the progression to CKD is the consequence of renal mass reduction due to the loss of nephrons during the acute stage. Hyperfiltration,[66] or abnormally elevated glomerular filtration rate (GFR), followed by significant and persistent albuminuria is the first marker of glomerular hypertension; however, it could appear several years later, especially in patients who have had a mild disease not requiring dialysis.[67]This is analogous to running a car 24 hours a day—it would be taxing on the vehicle, wearing it out faster. In the kidneys, it can lead to early nephron cell death.

Loss of the filtration units of the kidney—the nephrons—is permanent. Once a filter is gone, it is gone forever. When a lot of filters are gone, the remaining ones work harder because there are fewer of them. If enough filters are lost, the remaining filters experience “hyperfiltration,” which leads to enlargement, and over time, scarring, which in turn leads to the loss of more filters. 

Studies have shown a correlation between an increased number of days of anuria (lack of urination) or oliguria (decreased urination) and worse prognosis.[68] Patients who have been anuric/oliguric and required dialysis are at the highest risk for late complications; however, even those who were not dialyzed are not spared. Research has consistently shown that these patients commonly progress to chronic kidney disease within 5 years.

Acute Kidney Injury (AKI) is the term that has recently replaced the term ARF. AKI is defined as an abrupt (within hours) decrease in kidney function, which encompasses both injury (structural damage) and impairment (loss of function).[69] There are usually no symptoms until kidney function is at least moderately to severely impaired. When present, signs and symptoms of serious kidney injury reflect reduced filter function leading to buildup of toxic wastes, and may include high blood pressure, protein in the urine, swelling of the lower extremities, loss of appetite, nausea/vomiting, sleepiness, confusion, and difficulty thinking. It is easy to get a rough estimate of kidney filter function by looking at the level of waste products, especially creatinine in the blood over time. There are also formulas to estimate filter function using the creatinine value. The key is whether filter function changes over time. Since one of the primary functions of the kidneys is to regulate blood pressure, the development of hypertension after HUS also signals serious kidney injury and is considered a bad prognostic sign. So too is proteinuria—the passage of protein molecules in the urine—which is a sign that the glomeruli have been damaged, and the remaining filters are hyperfiltrating—i.e., they are being overworked due to the loss of filtering capacity related to nephron loss.

If enough filters are lost either due to injuries suffered during the acute HUS illness, or later in life due to the process of hyperfiltration, a patient will reach end stage renal disease (“ESRD”). ESRD, truly a worst-case scenario for someone who has survived the acute HUS illness, is a very painful process that can take decades to play out. The demands on the kidneys increase through puberty and, for women, especially during pregnancy, adding another variable to issues of future renal health for girls who have suffered severe HUS.

Long-term consequences of hemolytic uremic syndrome (HUS)

Multiple studies have demonstrated that children with HUS who have apparently recovered will develop hypertension, urinary abnormalities and/or renal insufficiency during long-term follow-up. One of the best predictors is the duration of anuria and/or oliguria.

Milford, et al, (J Pediatrics, 1991) studied the importance of proteinuria at one year following the acute episode of HUS in 40 children. They found that a poor prognosis defined as hypertension, decreased renal function or end stage renal disease was strongly associated with proteinuria at the one year follow up.

Perlstein et al, (Arch Dis Child, 1991) reported results of oral protein loading in 17 children with a history of HUS; they demonstrated that functional renal reserve was reduced in children with a history of HUS who had normal renal function and normal blood pressure as compared to normal children. This study suggests that functional renal reserve in children with HUS is reduced although renal function and blood pressure are normal. The authors point out that the long-term significance of this finding is unknown and needs to be determined but the study suggests that functional renal reserve may be reduced despite normal recovery and that children with HUS need long term follow-up.

In the article by Gagnadouz, et al, (Clinical Nephrology, 1996) 29 children were evaluated 15-25 years after the acute phase of HUS. Only 10 of the 29 children were normal, 12 had hypertension, 3 had chronic renal failure and 4 had end stage renal disease (65.5%). Severe sequelae occurred in children with oligo/anuria for more than or equal to 7 days.

Other studies (Caletti, et al, Pediatric Nephrology, 1996) have demonstrated that histological finding of focal and segmental sclerosis and hyalinosis are observed several years following HUS. In that article, only 25% of the children had normal renal function during long-term follow-up.

Similarly, Moghal, et al. (Journal of Pediatrics, 1998) performed kidney biopsies in children with persistent proteinuria three to seven years following the acute episode of HUS. Global glomerulosclerosis was noted in six of the seven patients and two had segmental sclerosis as well. In addition, tubular atrophy and interstitial fibrosis was seen in all but one. Finally, the glomeruli in the children with HUS were significantly larger than those in normal children. These are finding that are typically found in individual with reduced nephron number and are consistent with changes of hyperperfusion and hyperfiltration is surviving nephrons. Hyperfiltration is a process that frequently leads to progressive renal damage and the development of end stage renal failure.

In 1997 Spizzirri, et al, (Pediatr Nephrol, 1997), reported that 69.2% of children with 11 or more days of anuria and 38.4% of children with 1-10 days of anuria had chronic sequelae. In addition, of patients with proteinuria at the 1-year follow-up, 86% had renal abnormalities at the end of the follow-up. The authors suggested that children with residual proteinuria with or without hypertension would probably develop progressive chronic renal failure.

In 2002, Blahova, et al, reported that long term follow-up of 18 children who had HUS 10 or more years previously, only 6 children were normal while the other 12 children had either residual renal symptoms, chronic renal insufficiency, or renal failure (66.6%). Many of the children with residual renal symptoms or chronic renal insufficiency/renal failure had appeared to have recovered normally at earlier checkups.

Lou-Meda, et al, reported that 14 patients with microabluminuria and no overt proteinuria at 6 to 18 months after the acute phase of HUS, on long term follow up three had a decreased glomerular filtration (GFR), one had overt proteinuria, and four had hypertension. Eight of the 14 patients had at least one sequelae for an incidence of 57.1%. Six children had overt proteinuria and at the most recent follow up, two had hypertension, four and a low renal function and two had continued proteinuria; four (66.6%) had at least one renal sequela.

Recently, Oakes, et al, determined the risk of later complications in children who had HUS several years earlier; they found that the incidence of late complications increased markedly in those with more than 5 days of anuria or 10 days of oliguria. Among children with greater than 10 days of oliguria 63.3% had a low glomerular filtration rate, 33.3% had hypertension and 88.7% had at least one long term complication.

In the manuscript by Vaterrodt, et. al, the investigators noted that in a retrospective single center study, clinical and laboratory data of the acute phase and 1-10 year follow up visits were analyzed. The authors conclude that although renal outcomes have improved over the investigated decades, patients with HUS still had a high risk of permanent renal damage and that these findings underline the importance of a consequent long-term follow-up in HUS patients. 

In summary, many children who have recovered normal renal function following the acute episode of HUS have a high risk for the development of late complications from their acute episode of HUS. The risk is substantially lower in children who did not require dialysis and in children who were not oliguria or anuric while the risk is the highest in children who had oligo/anuria for more than 7 days. In one study, all children with oligo/anuria for 14 days had residual renal disease (100%).

As previously mentioned, some children who did not require dialysis had late complication of HUS. One third of the children in the study by Alconcher, et. al. (Pediat Neph, 2023 evolved into CKD after a median of 5 years. In addition, CKD appeared in some patients 15 years after the acute episode. In addition, these investigators reinforced that all non-dialyzed should be followed into adulthood. 

It is important to note that the risks of long-term (more than 20 years) complications are unknown and are likely to be higher than risks at 10 years as many of the above studies describe.

Long-term side effects of hemolytic uremic syndrome (HUS)

Adolescents and young adults with chronic kidney disease face several complications from their chronic kidney disease (Andreoli SP, Acute and Chronic Renal Failure in Children, 2009) including alterations in calcium and phosphate balance and renal osteodystrophy (softening of the bones, weak bones and bone pain), anemia (low blood count and lack of energy), hypertension (high blood pressure) as well as other complications.

Renal osteodystrophy (softening of the bones) is an important complication of chronic renal failure. Bone disease is nearly universal in patients with chronic renal failure; in some patients’ symptoms are minor to absent while others may develop bone pain, skeletal deformities and slipped epiphyses (abnormal shaped bones and abnormal hip bones) and have a propensity for fractures with minor trauma. Treatment of the bone disease associated with chronic renal failure includes control of serum phosphorus and calcium levels with restriction of phosphorus in the diet, supplementation of calcium, the need to take phosphorus binders and the need to take medications for bone disease.

Anemia (low blood cell count that leads to a lack of energy) is a very common complication of chronic renal failure. The kidneys make a hormone that tells the bone marrow to make red blood cells, and this hormone is not produced in sufficient amounts in children with chronic renal failure. Thus, children with chronic renal failure gradually become anemic while their chronic renal failure is slowly progressing. The anemia of chronic renal failure is treated with human recombinant erythropoietin (a shot given under the skin one to three times a week or once every few weeks with a longer acting human recombinant erythropoietin).

Renal replacement therapy can be in the form of dialysis (peritoneal dialysis or hemodialysis) or renal transplantation. The average waiting time for a deceased donor kidney for children aged 0-17 years is approximately 275-300 days while the average waiting time for patient’s aged 18-44 years is approximately 700 days (United States Renal Data Systems, Table 7.8, 2005).

Following transplantation, a patient will need to take immunosuppressive medications for the remainder of his/her life to prevent rejection of the transplanted kidney. Medications used to prevent rejection have considerable side effects. Corticosteroids are commonly used following transplantation. The side effects of corticosteroids are Cushingnoid features (fat deposition around the cheeks and abdomen and back), weight gain, emotional liability, cataracts, decreased growth, osteomalacia and osteonecrosis (softening of the bones and bone pain), hypertension, acne and difficulty in controlling glucose levels.

Cyclosporine and/or tacrolimus are also commonly used as immunosuppressive medications following transplantation. Side effects of these drugs include hirsutism (increased hair growth), gum hypertrophy, interstitial fibrosis in the kidney (damage to the kidney), as well as other complications. Meclophenalate is also commonly used after transplantation (sometimes imuran is used); each of these drugs can cause a low white blood cell count and increased susceptibility to infection. Many other immunosuppressive medications and other medications (anti-hypertensive agents, anti-acids, etc.) are prescribed in the postoperative period.

Lifelong immunosuppression as used in patients with kidney transplants is associated with several complications including an increased susceptibility to infection, accelerated atherosclerosis (hardening of the arteries) and increased incidence of malignancy (cancer) and chronic rejection of the kidney.

A patient may need more than one kidney transplant during his/her life. United States Renal Data Systems (USRDS) report that the half-life (time at which 50% of the kidneys are still functioning and 50% have stopped functioning) is 10.5 years for a deceased transplant in children aged 0-17 years and 15.5 years for a living related transplant in children 0-17 years. Similar data for a transplant at age 18 to 44 years is 10.1 years and 16.0 years for a deceased donor and a living related donor, respectively. Thus, depending upon age when the patient receives his/her first transplant he/she may need 1-2 transplants. The life expectancy of a person with a kidney transplant is significantly less than the general population and the life expectancy of person on dialysis a markedly less than the general population.

If a child needs a second kidney transplant after loss of his/her first transplant, he/she will need dialysis until a subsequent transplant can be performed. He/She can be on peritoneal dialysis or on hemodialysis. Peritoneal dialysis has been a major modality of therapy for chronic renal failure for several years. Continuous Ambulatory Peritoneal Dialysis (CAPD) and automated peritoneal dialysis also called Continuous Cycling Peritoneal Dialysis (CCPD) are the most common form of dialysis therapy used in children with chronic renal failure. In this form of dialysis, a catheter is placed in the peritoneal cavity (area around the stomach); dialysate (fluid to clean the blood) is placed into the abdomen and changed 4 to 6 times a day. Parents and adolescents can perform CAPD/CCPD at home. Peritonitis (infection of the fluid) is major complication of peritoneal dialysis.

E. coli O157:H7 and other Shiga-toxin producing E. coli are very dangerous bacteria – especially to children. The acute phase – even for those who do not progress to hemolytic uremic syndrome (HUS) – can be a painful and frightening experience. For those who progress to HUS, the risk of death is real. HUS has a mortality rate of 3-5%. And, even if the child survives, it may well be left with chronic health problems for the remainder of his/her life.

Other Medical Complications

Reactive Arthritis

Formerly referred to as Reiter Syndrome, the term reactive arthritis refers to an inflammation of one or more joints, following an infection localized at a site distant from the affected joints. The predominant site of the infection is the gastrointestinal tract. And reactive arthritis can be post-infection, meaning that the infection may not be active when diagnosed. Several other bacteria, including Salmonella, can cause reactive arthritis.[70] And although the resulting joint pain and inflammation can resolve completely over time, permanent joint damage can occur.[71]

The symptoms of reactive arthritis include pain and swelling in the knees, ankles, feet, and heels. Less frequently, the upper extremities may be affected, including the wrists, elbows, and fingers. Tendonitis (inflammation of the tendons) or enthesitis (inflammation where tendons attach to the bone) can occur. Other symptoms may include prostatitis, cervicitis, urethritis (inflammation of the prostate gland, cervix, or urethra), conjunctivitis (inflammation of the membrane lining the eyelid), or uveitis (inflammation of the inner eye). Ulcers and skin rashes are less common. Symptoms can range from mild to severe and can occur anywhere from three days to six weeks after the antecedent infection and may involve one or more joints, though usually six or fewer. Although most cases recover within a few months, some continue to experience complications for years. Treatment focuses on relieving the symptoms.[72]

Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract. The hallmark symptoms of IBS are abdominal pain and altered bowel habits, ranging from constipation to diarrhea, or alternating diarrhea and constipation. Abdominal pain is usually crampy in nature, but character and sites can vary. In some patients, the pain is relieved by defecation but, in others, defecation may worsen the pain. Additional symptoms may include bloating, straining at stools, and a sense of incomplete evacuation. The observation that the onset of IBS symptoms can be precipitated by gastrointestinal infection dates back to the 1950s. Mechanisms are not known but include changes in the microbiome, use of antibiotics to treat the infection, and an increase in enteroendocrine cells.

Another consequence of infective gastroenteritis is the disruption of normal gut flora. Studies on postinfectious IBS have provided etiological insights into the pathogenesis of IBS. It is well documented that following infective gastroenteritis, more than 10% of affected individuals go on to develop postinfectious IBS.[73] The risk of postinfectious IBS appears greater with bacterial gastroenteritis compared to viral gastroenteritis.


[1]           E. coli bacteria were discovered in the human colon in 1885 by German bacteriologist Theodor Escherich.  Feng, Peter, Stephen D. Weagant, Michael A. Grant, Enumeration of Escherichia coli and the Coliform Bacteria, in BACTERIOLOGICAL ANALYTICAL MANUAL (8th Ed. 2002), http://www.cfsan.fda.gov/~ebam/bam-4.html. Dr. Escherich also showed that certain strains of the bacteria were responsible for infant diarrhea and gastroenteritis, an important public health discovery. Id. Although the bacteria were initially called Bacterium coli, the name was later changed to Escherichia coli to honor its discoverer. Id.

[2]           Not all E. coli are motile. For example, E. coli O157:H7 which lack flagella are thus E. coli O157:NM for non-motile.

[3]           CDC, Escherichia coli O157:H7, General Information, Frequently Asked Questions: What is Escherichia coli O157:H7?, http://www.cdc.gov/ncidod/dbmd/diseaseinfo/escherichiacoli_g.htm.

[4]           Marion Nestle, Safe Food:  Bacteria, Biotechnology, and Bioterrorism, 40-41 (1st Pub. Ed. 2004).

[5]           James M. Jay, MODERN FOOD MICROBIOLOGY at 21 (6th ed. 2000). (“This is clearly the most widely studied genus of all bacteria.”)

[6]           Beth B. Bell, MD, MPH, et al. A Multistate Outbreak of Escherichia coli O157:H7-Associated Bloody Diarrhea and Hemolytic Uremic Syndrome from Hamburgers:  The Washington Experience, 272 JAMA (No. 17) 1349, 1350 (Nov. 2, 1994) (describing the multiple step testing process used to confirm, during a 1993 outbreak, that the implicated bacteria were E. coli O157:H7).

[7]           Jay, supra note 5, at 220-21 (describing in brief the PFGE testing process).

[8]           Id.  Through PFGE testing, isolates obtained from the stool cultures of probable outbreak cases can be compared to the genetic fingerprint of the outbreak strain, confirming that the person was in fact part of the outbreak. Bell, supra note 6, at 1351-52. Because PFGE testing soon proved to be such a powerful outbreak investigation tool, PulseNet, a national database of PFGE test results was created.  Bala Swaminathan, et al.  PulseNet:  The Molecular Subtyping Network for Foodborne Bacterial Disease Surveillance, United States, 7 Emerging Infect. Dis. (No. 3) 382, 382-89 (May-June 2001) (recounting the history of PulseNet and its effectiveness in outbreak investigation).

[9]           Konno T. et al.  Application of a multilocus variable number of tandem repeats analysis to regional outbreak surveillance of Enterohemorrhagic Escherichia coli O157:H7 infections. Jpn J Infect Dis. 2011 Jan; 64(1): 63-5.

[10]         “[A] type of gastroenteritis in which certain strains of the bacterium Escherichia coli (E. coli) infect the large intestine and produce a toxin that causes bloody diarrhea and other serious complications.”  The Merck Manual of Medical Information, 2nd Home Ed. Online, http://www.merck.com/mmhe/sec09/ch122/ch122b.html.

[11]         L. Riley, et al.  Hemorrhagic Colitis Associated with a Rare Escherichia coli Serotype, 308 New. Eng. J. Med. 681, 684-85 (1983) (describing investigation of two outbreaks affecting at least 47 people in Oregon and Michigan both linked to apparently undercooked ground beef).  Chinyu Su, MD & Lawrence J. Brandt, MD, Escherichia coli O157:H7 Infection in Humans, 123 Annals Intern.  Med. (Issue 9), 698-707 (describing the epidemiology of the bacteria, including an account of its initial discovery).

[12]         Riley, supra note 11 at 684. See also Patricia M. Griffin & Robert V. Tauxe, The Epidemiology of Infections Caused by Escherichia coliO157:H7, Other Enterohemorrhagic E. coli, and the Associated Hemolytic Uremic Syndrome, 13 Epidemiologic Reviews 60, 73 (1991).

[13]         Peter Feng, Escherichia coli Serotype O157:H7:  Novel Vehicles of Infection and Emergence of Phenotypic Variants, 1 Emerging Infect. Dis. (No. 2), 47, 47 (April-June 1995) (noting that, despite these earlier outbreaks, the bacteria did not receive any considerable attention until ten years later when an outbreak occurred 1993 that involved four deaths and over 700 persons infected).

[14]         William E. Keene, et al.  A Swimming-Associated Outbreak of Hemorrhagic Colitis Caused by Escherichia coli O157:H7 and Shigella Sonnei, 331 New Eng. J. Med. 579 (Sept. 1, 1994).  See also Stephen M. Ostroff, MD, John M. Kobayashi, MD, MPH, and Jay H. Lewis, Infections with Escherichia coli O157:H7 in Washington State:  The First Year of Statewide Disease Surveillance, 262 JAMA (No. 3) 355, 355 (July 21, 1989).  (“It was anticipated the reporting requirement would stimulate practitioners and laboratories to screen for the organism.”)

[15]         See Keene, supra note 14 at 583. (“With cases scattered over four counties, the outbreak would probably have gone unnoticed had the cases not been routinely reported to public health agencies and investigated by them.”)  With improved surveillance, mandatory reporting in 48 states, and the broad recognition by public health officials that E. coli O157:H7 was an important and threatening pathogen, there were a total of 350 reported outbreaks from 1982-2002. Josef M. Rangel, et al.  Epidemiology of Escherichia coli O157:H7 Outbreaks, United States, 1982-2002, 11 Emerging Infect. Dis. (No. 4) 603, 604 (April 2005).

[16]         Griffin & Tauxe supra note 12, at 61-62 (noting that the nomenclature came about because of the resemblance to toxins produced by Shigella dysenteries).

[17]         Sanding K, Pathways followed by ricin and Shiga toxin into cells, Histochemistry and Cell Biology, vol. 117, no. 2:131-141 (2002). Endothelial cells line the interior surface of blood vessels.  They are known to be extremely sensitive to E. coli O157:H7, which is cytotoxigenic to these cells making them a primary target during STEC infections.

[18]         Johannes L, Shiga toxins—from cell biology to biomedical applications.  Nat Rev Microbiol 8, 105-116 (February 2010).  Suh JK, et al.  Shiga Toxin Attacks Bacterial Ribosomes as Effectively as Eucaryotic Ribosomes, Biochemistry, 37 (26); 9394–9398 (1998).

[19]         Welinder-Olsson C, Kaijser B.  Enterohemorrhagic Escherichia coli (EHEC).  Scand J. Infect Dis. 37(6-7): 405-16 (2005).  See alsoUSDA Food Safety Research Information Office E. coli O157:H7 Technical Fact Sheet:  Role of 60-Megadalton Plasmid (p0157) and Potential Virulence Factors, http://fsrio.nal.usda.gov/document_fsheet.php?product_id=225.

[20]         Kaper JB and Karmali MA.  The Continuing Evolution of a Bacterial Pathogen.  PNAS vol. 105 no. 12 4535-4536 (March 2008).  Wick LM, et al.  Evolution of genomic content in the stepwise emergence of Escherichia coli O157:H7.  J Bacteriol 187:1783–1791(2005).

[21]         A group of biological taxa (as species) that includes all descendants of one common ancestor.

[22]         Zhang W, et al.  Probing genomic diversity and evolution of Escherichia coli O157 by single nucleotide polymorphisms. Genome Res 16:757–767 (2006).

[23]         Robins-Browne RM. The relentless evolution of pathogenic Escherichia coli.  Clin Infec Dis. 41:793–794 (2005).

[24]         Manning SD, et al. Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks. PNAS vol. 105 no. 12 4868-4873 (2008).  (“These results support the hypothesis that the clade 8 lineage has recently acquired novel factors that contribute to enhanced virulence.  Evolutionary changes in the clade 8 subpopulation could explain its emergence in several recent foodborne outbreaks; however, it is not clear why this virulent subpopulation is increasing in prevalence.”)

[25]         Robert A. Tauxe, Emerging Foodborne Diseases: An Evolving Public Health Challenge, 3 Emerging Infect. Dis. (No. 4) 425, 427 (Oct.-Dec. 1997).  (“After 15 years of research, we know a great deal about infections with E. coli O157:H7, but we still do not know how best to treat the infection, nor how the cattle (the principal source of infection for humans) themselves become infected.”)

[26]         CDC, Multistate Outbreak of Escherichia coli O157:H7 Infections Associated With Eating Ground Beef—United States, June-July 2002, 51 MMWR 637, 638 (2002) reprinted in 288 JAMA (No. 6) 690 (Aug. 14, 2002).

[27]         Rangel, supra note 15, at 605.

[28]         Feng, supra note 13, at 49. See also USDA Bad Bug Book, Escherichia coli O157:H7, http://www.fda.gov/food/foodsafety/foodborneillness/foodborneillnessfoodbornepathogensnaturaltoxins/badbugbook/ucm071284.htm.

[29]         Scallan E, et al.  Foodborne illness acquired in the United States –major pathogens, Emerging Infect. Dis. Jan. (2011), http://www.cdc.gov/EID/content/17/1/7.htm. Note: CDC has since updated its estimates. Current figures (2024) report 97,000 illnesses, 3,270 hospitalizations, and 30 deaths annually from STEC O157. See CDC, Technical Information on E. coli, https://www.cdc.gov/ecoli/php/technical-info/index.html.

[30]         Id., Table 3.

[31]         Griffin & Tauxe supra note 12, at 63.

[32]         Centers for Disease Control, Division of Foodborne, Bacterial and Mycotic Diseases, Escherichia coli general information, http://www.cdc.gov/nczved/dfbmd/disease_listing/stec_gi.html.  See also PROCEDURES TO INVESTIGATE FOODBORNE ILLNESS, 107 (IAFP 5th Ed. 1999) (identifying incubation period for E. coli O157:H7 as “1 to 10 days, typically 2 to 5”).

[33]         Su & Brandt, supra note 11 (“the young are most often affected”).

[34]         Tauxe, supra note 25, at 1152.

[35]         Id.

[36]         Griffin & Tauxe supra note 12, at 72. (“The general patterns of transmission in these outbreaks suggest that the infectious dose is low.”)

[37]         V.K. Juneja, O.P. Snyder, A.C. Williams, and B.S. Marmer, Thermal Destruction of Escherichia coli O157:H7 in Hamburger, 60 J. Food Prot. (vol. 10). 1163-1166 (1997) (demonstrating that, if hamburger does not get to 130°F, there is no bacterial destruction, and at 140°F, there is only a 2-log reduction of E. coli present).

[38]         Griffin & Tauxe supra note 12, at 72 (noting that, as a result, “fewer bacteria are needed to cause illness that for outbreaks of salmonellosis”). Nestle, supra note 4, at 41. (“Foods containing E. coli O17:H7 must be at temperatures high enough to kill all of them.”) (italics in original)

[39]         Patricia M. Griffin, et al.  Large Outbreak of Escherichia coli O157:H7 Infections in the Western United States:  The Big Picture, in RECENT ADVANCES IN VEROCYTOTOXIN-PRODUCING ESCHERICHIA COLI INFECTIONS, at 7 (M.A. Karmali & A. G. Goglio eds. 1994).  (“The most probable number of E. coli O157:H7 was less than 20 organisms per gram.”)  There is some inconsistency with regard to the reported infectious dose.  Compare Chryssa V. Deliganis, Death by Apple Juice:  The Problem of Foodborne Illness, the Regulatory Response, and Further Suggestions for Reform, 53 Food Drug L.J. 681, 683 (1998) (“as few as ten”) with Nestle, supra note 4, at 41 (“less than 50”). Regardless of these inconsistencies, everyone agrees that the infectious dose is, as Dr. Nestle has put it, “a miniscule number in bacterial terms.”  Id.

[40]         Nestle, supra note 4, at 41.

[41]         Griffin & Tauxe supra note 12, at 72. The apparent “ease of person-to-person transmission…is reminiscent of Shigella, an organism that can be transmitted by exposure to extremely few organisms.”  Id.  As a result, outbreaks in places like daycare centers have proven relatively common.  Rangel, supra note 15, at 605-06 (finding that 80% of the 50 reported person-to-person outbreak from 1982-2002 occurred in daycare centers).

[42]         See, e.g. National Academy of Science, Escherichia coli O157:H7 in Ground Beef: Review of a Draft Risk Assessment, Executive Summary, at 7 (noting that the lack of data concerning the impact of cross-contamination of E. coli O157:H7 during food preparation was a flaw in the Agency’s risk-assessment), http://www.nap.edu/books/0309086272/html/.

[43]         Kriefall v. Excel, 265 Wis.2d 476, 506, 665 N.W.2d 417, 433 (2003).  (“Given the realities of what it saw as consumers’ food-handling patterns, the [USDA] bored in on the only effective way to reduce or eliminate food-borne illness”—i.e., making sure that “the pathogen had not been present on the raw product in the first place.”)  (Citing Pathogen Reduction, 61 Fed. Reg. at 38966).

[44]         Griffin & Tauxe, supra note 10, at 65-68. See also Josefa M. Rangel, et al., Epidemiology of Escherichia coli O157:H7 Outbreaks, United States, 1982-2002, 11 Emerging Infect. Dis. (No. 4) 603 (April 2005) (noting that HUS is characterized by the diagnostic triad of hemolytic anemia—destruction of red blood cells, thrombocytopenia—low platelet count, and renal injury—destruction of nephrons often leading to kidney failure); Richard L. Siegler, MD, The Hemolytic Uremic Syndrome, 42 Ped. Nephrology, 1505 (Dec. 1995) (noting that the diagnostic triad of hemolytic anemia, thrombocytopenia, and acute renal failure was first described in 1955).

[45]         Siegler, supra note 35 at 1505. (“[HUS] is now recognized as the most frequent cause of acute renal failure in infants and young children.”) See also Beth P. Bell, MD, MPH, et al., Predictors of Hemolytic Uremic Syndrome in Children During a Large Outbreak of Escherichia coli O157:H7 Infections, 100 Pediatrics 1, 1 (July 1, 1997), at http://www.pediatrics.org/cgi/content/full/100/1/e12.

[46]         Tauxe, supra note 17, at 1152. See also Nasia Safdar, MD, et al., Risk of Hemolytic Uremic Syndrome After Treatment of Escherichia coliO157:H7 Enteritis: A Meta-analysis, 288 JAMA (No. 8) 996, 996 (Aug. 28, 2002).  (“E. coli serotype O157:H7 infection has been recognized as the most common cause of HUS in the United States, with 6% of patients developing HUS within 2 to 14 days of onset of diarrhea.”); Amit X. Garg, MD, MA, et al., Long-term Renal Prognosis of Diarrhea-Associated Hemolytic Uremic Syndrome: A Systematic Review, Meta-Analysis, and Meta-regression, 290 JAMA (No. 10) 1360, 1360 (Sept. 10, 2003). (“Ninety percent of childhood cases of HUS are…due to Shiga-toxin producing Escherichia coli.”)

[47]         Su & Brandt, supra note 9.

[48]         Safdar, supra note 37, at 996 (going on to conclude that administration of antibiotics to children with E. coli O157:H7 appeared to put them at higher risk for developing HUS).

[49]         Richard L. Siegler, MD, Postdiarrheal Shiga Toxin-Mediated Hemolytic Uremic Syndrome, 290 JAMA (No. 10) 1379, 1379 (Sept. 10, 2003).

[50]         Pierre Robitaille, et al., Pancreatic Injury in the Hemolytic Uremic Syndrome, 11 Pediatric Nephrology 631, 632 (1997) (“although mild pancreas involvement in the acute phase of HUS can be frequent”).

[51]         Safdar, supra note 37, at 996; see also Siegler, supra note 35, at 1379. (“There are no treatments of proven value, and care during the acute phase of the illness, which is merely supportive, has not changed substantially during the past 30 years.”)

[52]         Su & Brandt, supra note 9 (“the mortality rate is 5-10%”). See also Kriefall, 265 N.W.2d at 483 (“three-year old Brianna Kriefall died from food that everyone party to this appeal…recognize was cross-contaminated by E. coli O157:H7 bacteria from meat sold by Excel.”)

[53]         Garg, supra note at 1360.

[54]         Id. Siegler, supra note, at 1509-11 (describing what Dr. Siegler refers to as the “pathogenic cascade” that results in the progression from colitis to HUS).

[55]         Garg, supra note at 1360. See also Su & Brandt, supra note 11, at 700.

[56]         Garg, supra note, at 1360. See also Su & Brandt, supra note 11, at 700.

[57]         Siegler, supra note, at 1519 (noting that in a “20-year Utah-based population study, 5% dies, and an equal number of survivors were left with end-stage renal disease (ESRD) or chronic brain damage.”)

[58]         Garg, supra note at 1366-67.

[59]         Siegler, supra note, at 1519.

[60]         Id. at 1519-20. See also Garg, supra at 1366-67.

[61]         Garg, supra note at 1368.

[62]         Chan, Y.S., Ng, T.B. Shiga toxins: From structure and mechanism to applications. (2016). Appl Microbiol Biotechnol 100, 1597–1610. https://doi.org/10.1007/s00253-015-7236-3

[63]         HUS is thrombotic microangiopathy characterized by the presence of a triad of symptoms: thrombocytopenia, acute renal impairment, and microangiopathic hemolytic anemia. Bhandari, J., & Sedhai, Y. R. Hemolytic uremic syndrome (HUS). (2020). State University of New York. https://www.researchgate.net/publication/341925697

[64]         Falkson SR, Bordoni B. Anatomy, Abdomen and Pelvis, Bowman Capsule. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2022. PMID: 32119361. https://europepmc.org/article/NBK/nbk554474

[65]         Renal biopsies are not routinely carried out as HUS diagnoses are usually clinically derived and patients are usually thrombocytopenic. Obrig, T. G., & Karpman, D. (2012). Shiga toxin pathogenesis: kidney complications and renal failure. Ricin and Shiga Toxins: Pathogenesis, Immunity, Vaccines and Therapeutics, 105-136. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779650/

[66]         Helal, I., Fick-Brosnahan, G. M., Reed-Gitomer, B., & Schrier, R. W. (2012). Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nature Reviews Nephrology8(5), 293-300.

[67]         Alconcher, L. F., Lucarelli, L. I., & Bronfen, S. (2023). Long-term kidney outcomes in non-dialyzed children with Shiga-toxin Escherichia coli associated hemolytic uremic syndrome. Pediatric Nephrology38(7), 2131-2136. https://link.springer.com/article/10.1007/s00467-022-05851-4

[68]         Pundzienė, B., Dobilienė, D., Čerkauskienė, R., Mitkienė, R., Medzevičienė, A., Darškuvienė, E., Jankauskienė, A. (2015). Long-term follow-up of children with typical hemolytic uremic syndrome. (2015). Medicina 51(3)146-151. https://doi.org/10.1016/j.medici.2015.06.004

[69]         Makris, K., & Spanou, L. (2016). Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes. The Clinical biochemist. Reviews37(2), 85–98.

[70]         See “Reactive Arthritis.” Questions and Answers About. N.p., n.d. Web. 12 Nov. 2015.

[71]         Id.

[72]         “Reactive Arthritis.” National Institute of Arthritis and Musculoskeletal and Skin Diseases, Oct. 2016. Available at: https://www.niams.nih.gov/health-topics/reactive-arthritis

[73]         Ng, Q. X., Soh, A., Loke, W., Lim, D. Y., & Yeo, W. S. (2018). The role of inflammation in irritable bowel syndrome (IBS). Journal of inflammation research11, 345–349. https://doi.org/10.2147/JIR.S174982

Announced yesterday, the CDPH is working with local health departments and federal partners to investigate an STEC O157:H7 outbreak linked to the consumption of beef kofta served at several California locations of The Kebab Shop restaurant chain. The Kebab Shop has voluntarily paused sales of grilled beef kofta at all locations. As of May 19, 2026, nine California residents have been infected with the outbreak strain of STEC O157:H7. Illness onset dates range from March 27 through April 30, 2026. Six illnesses are in children. Five individuals have been hospitalized, and two have developed HUS – acute kidney failure.

I have spent more than thirty years watching children fight for their lives because someone served them an undercooked hamburger. I have sat with parents in hospital waiting rooms while their kids lay in kidney failure. I have carried those cases into courtrooms, into congressional hearing rooms, and into the court of public opinion — and I will keep carrying them until the industry and the regulators do what they should have done long ago.

This is a record of what we have done, what it cost, and what it changed. The ground beef industry in America is measurably safer today than it was in 1993. That didn’t happen by accident. It happened because sick children and grieving families refused to be silenced, and because Marler Clark refused to stop.

1993 — Jack in the Box — Multistate

This is where it all began for me. The Jack in the Box E. coli O157:H7 outbreak was a catastrophe — hundreds sickened, dozens hospitalized with kidney failure, four children dead. The attorneys who would go on to found Marler Clark handled most of the resulting litigation, eventually securing individual and class-action settlements totaling more than $50 million — the largest food-borne illness payments the country had ever seen.

My client was Brianne Kiner, nine years old. She spent 42 days in a coma. She suffered kidney failure and permanent neurological damage. I won her a $15.6 million settlement. That case launched my career, and it never left me. Every case I have taken since has had Brianne’s face somewhere behind it.

1994 — USDA Declares E. coli O157:H7 an Adulterant in Ground Beef

The single most important food safety regulatory action I have witnessed in my career happened the year after Jack in the Box. FSIS Administrator Michael Taylor declared E. coli O157:H7 an adulterant in raw ground beef — meaning it was now illegal to sell hamburger contaminated with this pathogen. The USDA also mandated safe handling labels, required HACCP plans, and raised cook temperature requirements for the restaurant industry.

The meat industry fought it. The American Meat Institute sued to block the rule. It took years to fully take hold. But once it did, the numbers told the story: from 1993 to around 2002, roughly 95% of Marler Clark’s revenue came from hamburger E. coli cases. By 2003, major ground beef outbreaks had become rare. That is what a serious regulatory decision looks like. That is what accountability produces.

1998 — Bauer Meat — Georgia

Marler Clark litigated E. coli O157:H7 cases tied to contaminated ground beef produced by Bauer Meat in Georgia. Outbreaks don’t always make national headlines. The families hurt by them suffer just as much.

1999 — Golden Corral — Nebraska

Nearly 80 people were sickened in a Golden Corral E. coli outbreak in central Nebraska. We represented the victims. Eighty people is not a statistic — it’s a community.

2000 — AFG / Supervalu — Minnesota

Marler Clark represented victims of an E. coli O157:H7 outbreak linked to ground beef distributed through AFG/Supervalu grocery stores in Minnesota. Contaminated beef reached families through their neighborhood grocery stores.

2001 — Excel — Georgia

We represented the family of a 12-year-old boy from Norcross, Georgia, infected with E. coli O157:H7 linked to Excel brand ground beef. Twelve years old. A hamburger should not be a life-threatening meal.

2002 — Emmpak — Wisconsin

The USDA-FSIS closed one Emmpak plant for inadequate sampling and testing. By then, 57 people had been sickened by adulterated ground beef — 35 of them in Wisconsin. We represented the victims. The plant was shut down not because the company chose to do the right thing, but because the government finally forced them to.

2002 — BJ’s Wholesale Club — New York & New Jersey

Marler Clark filed E. coli lawsuits related to contaminated ground beef sold at BJ’s Wholesale Club locations in the Northeast. Warehouse retailers selling bulk ground beef carry the same responsibility as anyone else in the supply chain.

2002 — ConAgra Ground Beef — Nationwide

ConAgra is the outbreak that crystallized everything for me about corporate accountability and regulatory failure happening simultaneously. We represented 33 victims — including six children who developed hemolytic uremic syndrome (HUS) and the family of an Ohio woman who died. ConAgra recalled 18.6 million pounds of ground beef from its Greeley, Colorado plant — the second largest meat recall in U.S. history at the time. The USDA subsequently shut down the Greeley plant for repeated failures to prevent fecal contamination. Claims were resolved in 2004.

Eighteen-point-six million pounds. Think about what that number means. And the plant had to be shut down by regulators — it did not shut itself down.

2002 — Congressional Testimony and the “Put Me Out of Business” Op-Ed

After ConAgra and Emmpak, I went to Congress. I testified about the systemic failures that allowed contaminated ground beef to keep reaching American families. And I wrote an op-ed in leading publications with a message I meant literally: the USDA should make my hamburger practice unnecessary by doing its job.

I called on the USDA to:

  • Hire more inspectors and give them real authority to sample meat and stop distribution when pathogens are detected.
  • Implement a sampling system that provides a reasonable chance of actually preventing outbreaks — not just documenting them afterward.
  • Grant mandatory recall authority for contaminated products.
  • Support Senator Tom Harkin’s Safer Meat, Poultry and Foods Act — Kevin’s Law — named for a child who died of E. coli.

The industry didn’t want mandatory recalls then. They still resist meaningful enforcement today. But every outbreak that follows a preventable failure is an argument for exactly the kind of accountability I was calling for.

2004 — Carneco / Sam’s Club — Wisconsin & Minnesota

We filed an E. coli lawsuit against Carneco on behalf of a nine-year-old boy who ate “Northern Plains” frozen ground beef patties purchased at Sam’s Club. The outbreak prompted federal authorities to recall nearly 500,000 pounds of product. A nine-year-old. A bag of frozen burger patties. This keeps happening.

2005 — Flanders Provision Co. — Colorado / Nationwide

Marler Clark litigated E. coli cases stemming from contaminated ground beef produced by Flanders Provision Co., affecting victims in Colorado and across other states.

2007 — Cargill Hamburger — Minnesota, Tennessee

Ground beef produced by Cargill and sold at Sam’s Club was the source of an E. coli O157:H7 outbreak that prompted a recall of approximately 845,000 pounds of frozen patties. We represented 14 victims.

Stephanie Smith was 22 years old, a dance instructor from Cold Spring, Minnesota. She developed HUS and was left paralyzed from the waist down. Stephanie’s story became the subject of a Pulitzer Prize–winning investigation by New York Times reporter Michael Moss, who traced her burger through the entire supply chain and exposed the industry’s practice of blending trim from multiple processors with minimal testing. Stephanie settled her lawsuit against Cargill Meat Solutions.

A 22-year-old woman lost the use of her legs because of a hamburger. She deserved better. So did every other victim in that outbreak. So does every American who eats ground beef.

2007 — Fresno Meat Market — California

Marler Clark filed E. coli lawsuits on behalf of victims sickened by contaminated ground beef sold at a meat market in Fresno, California. Local butcher shops and small retailers carry the same food safety obligations as the biggest processors in the country.

2007 — Topps Meats — Nationwide

We filed two lawsuits against Topps Meats — one in Albany, one in Ithaca, New York — on behalf of families whose children were hospitalized after eating Topps hamburgers. Topps Meats went out of business as a result of the outbreak and recall. That is one form of accountability. It is a harsh one, and it comes too late for the families involved.

2009 — Fairbank Farms — Nationwide

Marler Clark filed E. coli lawsuits after Fairbank Farms recalled E. coli O157:H7-tainted ground beef affecting consumers across multiple states, primarily in New England and the Mid-Atlantic.

2008–2009 — $500,000 Ground Beef Testing Study and Non-O157 Petition

I was increasingly concerned that non-O157 Shiga toxin-producing E. coli strains — STECs other than O157:H7 — were sickening Americans but received almost no regulatory attention because they weren’t classified as adulterants. So I did something about it. I personally funded a major scientific study, which ultimately cost approximately $500,000, in partnership with microbiologist Dr. Mansour Samadpour of the Seattle-based Institute for Environmental Health.

We tested 5,000 large retail packages of ground beef purchased at stores across the country for all strains of E. coli. The results showed approximately 2% contamination by non-O157 STEC strains. Given that Americans eat billions of pounds of ground beef annually, a 2% rate meant millions of pounds of potentially dangerous meat reaching consumers every year — and regulators weren’t even required to look for it.

I briefed USDA scientists three times. I shared the findings with the National Meat Association and the American Meat Institute. The agency took no meaningful action. So in 2009, Marler Clark filed a formal citizen’s petition with FSIS demanding that non-O157 STECs be declared adulterants in ground beef and beef trim. When the agency failed to respond as required by law, I threatened to sue. At that point, USDA formally acknowledged receipt.

2012 — USDA Declares Six Additional E. coli Strains Adulterants

It took years. It took congressional advocacy, sustained public pressure, and a formal legal petition that I was prepared to litigate. But in 2012, FSIS officially declared six additional non-O157 STEC strains adulterants in ground beef and beef products:

  • E. coli O26
  • E. coli O45
  • E. coli O103
  • E. coli O111
  • E. coli O121
  • E. coli O145

FSIS simultaneously began mandating testing of ground beef, beef trim, and machine-tenderized steaks for these pathogens. Illnesses from non-O157 STEC strains in ground beef subsequently declined. That is a direct result of Marler Clark’s 2009 petition and the pressure we applied over years. I am proud of that — not because of the litigation, but because people stopped getting sick.

2018 — Cargill — Multistate

Marler Clark litigated a second major E. coli outbreak linked to Cargill ground beef products distributed across multiple states. When the same company appears in your case files more than once, it tells you something about whether accountability is working.

2020 — Marler Clark Petitions USDA to Declare Salmonella an Adulterant

On January 19, 2020, Marler Clark filed a formal petition with USDA-FSIS on behalf of Rick Schiller, Steven Romes, the Porter Family, Food & Water Watch, Consumer Federation of America, and Consumer Reports. We asked the agency to declare 31 Salmonella outbreak serotypes as adulterants in meat and poultry — applying the same regulatory strategy that transformed ground beef safety to the even larger and more deadly problem of Salmonella in poultry.

The petition was denied without prejudice. I continue to advocate for this change. What worked for E. coli in beef can work for Salmonella in chicken. The beef industry’s own experience demonstrates it: declaring a pathogen an adulterant, while initially opposed by industry, ultimately leads to safer products and fewer deaths. The poultry industry will learn the same lesson — the question is only how many people have to get sick first.

2024 — Montana Wagyu Beef / Lower Valley Processing — Flathead County

This outbreak brought me back to the 1990s in the worst way. Wagyu beef processed by Lower Valley Processing was served as undercooked or made-to-order burgers at multiple Flathead County restaurants — Gunsight Saloon, Hops Downtown Grill, Tamarack Brewing Company, the Lodge at Whitefish Lake, and Harbor Grille. Twenty-two cases were identified across 10 states. Two people died.

Marler Clark filed the initial E. coli lawsuit, then amended it to name Lower Valley Processing and Range MT as the source of the contaminated wagyu beef — lot numbers 1398, 1399, and 1400. We subsequently filed a wrongful death lawsuit on behalf of a victim’s family.

The “rare burger” problem is not new. I have been talking about it for decades. When a restaurant offers a made-to-order or “rare” burger preparation, they are taking a public health risk with their customers’ lives. The regulatory framework built around E. coli and ground beef does not protect people from undercooking. Two people died in Montana in 2024 for the same reason children died in Jack in the Box restaurants in 1993. That is unacceptable.

The Impact: What Thirty Years Has Produced

Let me be direct about what this work has accomplished, because it matters and because the numbers are real.

In the early 1990s, ground beef was among the most dangerous foods in the American diet. E. coli O157:H7 outbreaks linked to hamburgers were common — hundreds sickened at a time, children dying, families shattered. By the mid-2000s, major ground beef outbreaks had become rare. The combination of the 1994 adulterant declaration, HACCP implementation, higher cook temperature requirements, more robust industry testing, and sustained legal accountability through Marler Clark’s litigation produced a measurable, lasting reduction in illness and death.

Our practice shifted almost entirely to other foods — leafy greens, sprouts, raw milk, produce. That is not a complaint. That is a report on progress.

But the 2024 Montana outbreak is a reminder that progress is not permanence. The risk never fully disappears — particularly when ground beef is served undercooked, when supply chains grow complex, or when vigilance fades. The regulatory framework built around E. coli and ground beef remains one of the genuine success stories of American food safety policy. It is also a model and a rebuke: a model for what the government can accomplish when it declares a pathogen illegal and enforces that declaration, and a rebuke to every agency that has failed to apply the same logic to Salmonella, to Listeria, to the pathogens that continue to kill Americans today.

I have spent thirty years trying to put myself out of business. I’m not there yet. But the ground beef cases show it’s possible — and that’s worth fighting for.

William “Bill” Marler has been a food safety lawyer and advocate since the 1993 Jack-in-the-Box E. coli Outbreak which was chronicled in the book, “Poisoned” and in the recent Emmy Award winning Netflix documentary by the same name. Bill work has been profiled in the New Yorker, “A Bug in the System;” the Seattle Times, “30 years after the deadly E. coli outbreak, A Seattle attorney still fights for food safety;” the Washington Post, “He helped make burgers safer, Now he is fighting food poisoning again;” and several others. 

Dozens of times a year Bill speaks to industry and government throughout the United States, Canada, Europe, Africa, China and Australia on why it is important to prevent foodborne illnesses.  He is also a frequent commentator on food litigation and food safety on Marler Blog. Bill is also the publisher of Food Safety News.

The Los Angeles County Department of Public Health (LAC DPH) today announced it is investigating a cluster of Brucella melitensis (brucellosis) infections among adults residing in South Los Angeles County. Each confirmed case reported consuming unpasteurized cheese imported from Mexico, underscoring the serious health risks associated with raw or unpasteurized dairy products.

Brucellosis is rare in Los Angeles County, with fewer than 15 cases reported annually. Most local cases are associated with unpasteurized imported cheese, occupational exposure to animals abroad, or accidental laboratory exposures. While the current risk to the general public remains low, LAC DPH is issuing this advisory to alert healthcare providers and the public to the ongoing investigation.

“Consuming raw or unpasteurized dairy products carries significant risk of serious infection. We urge all residents to avoid these products, whether purchased locally or brought by family and friends from abroad.”

— Dr. Sharon Balter, Director, Acute Communicable Disease Control Program, LAC DPH

About Brucellosis

Brucellosis — also known as “Malta fever,” “undulant fever,” or “Mediterranean fever” — is considered one of medicine’s “great imitators” due to its wide range of symptoms. The bacteria enter the bloodstream via regional lymph nodes and can seed throughout the body. The incubation period ranges from one to four weeks but may be as long as six months.

Symptoms include acute or insidious onset of fever, night sweats, arthralgia, headache, fatigue, anorexia, myalgia, and weight loss. In serious cases, the infection can cause arthritis, spondylitis, meningitis, endocarditis, orchitis/epididymitis, and organ involvement affecting the liver and spleen.

Brucella species are designated federal Select Agents due to their low infectious dose and potential for aerosolization. Laboratories must be alerted before specimens from a suspect brucellosis case are submitted.

Guidance for Healthcare Providers

Healthcare providers are asked to take the following steps:

  • Suspect: Consider brucellosis in patients with fever, night sweats, fatigue, or arthralgias who have a history of consuming unpasteurized dairy products in the U.S. or during travel to endemic countries.
  • Test: Order Brucella serology and blood cultures. Notify the laboratory before submitting specimens so appropriate biosafety precautions can be taken.
  • Treat: Consult an infectious disease physician. Standard treatment is doxycycline for 6 weeks plus streptomycin (14–21 days) or rifampin (6 weeks). For pediatric or pregnant patients, consider rifampin plus TMP-SMX. Begin treatment without waiting for lab confirmation if clinical suspicion is high.
  • Post-Exposure Prophylaxis (PEP): Consider PEP for individuals exposed to a common contaminated product or who had high-risk exposure to a confirmed case, along with serologic and symptom monitoring.
  • Report: Brucellosis must be reported to Public Health within one working day. If a cluster of two or more related cases is suspected, notify Public Health immediately.
  • Educate: Advise patients to avoid all raw or unpasteurized dairy products — including those with unknown pasteurization status — whether purchased locally or during travel.

Guidance for the Public

LAC DPH advises all residents to avoid consuming raw or unpasteurized dairy products, including cheese informally brought into the country by family or friends, or consumed while traveling to regions where brucellosis is endemic. Individuals who have recently consumed unpasteurized imported cheese and are experiencing fever, night sweats, fatigue, or joint pain should consult a healthcare provider promptly.

Reporting Information

To report suspected cases or clusters:

  • LA County DPH Acute Communicable Disease Control (weekdays 8:30am–5:00pm): 213-240-7941 | After hours: 213-974-1234
  • Long Beach Health and Human Services (weekdays 8:00am–5:00pm): 562-570-4302 | After hours: 562-500-5537
  • Pasadena Public Health Department (weekdays 8:00am–5:00pm): 626-744-6089 | After hours: 626-744-6043

As of May 19, 2026, nine California residents have been infected with the outbreak strain of STEC O157:H7. Illness onset dates range from March 27 through April 30, 2026. Six illnesses are in children. Five individuals have been hospitalized, and two have developed HUS. No deaths have been reported. No individuals from other states are currently linked to this outbreak. 

The California Department of Public Health (CDPH) is advising consumers to be aware of possible exposure to Shiga toxin-producing E. coli (STEC) O157:H7 bacteria from consumption of beef kofta (seasoned ground beef kebabs) served at The Kebab Shop restaurant chain locations in Northern and Southern California. Consumers should call their health care provider if they become sick with symptoms of STEC infection within 10 days of eating this product. 

CDPH is working with local health departments and federal partners to investigate an STEC O157:H7 outbreak linked to the consumption of beef kofta served at several California locations of The Kebab Shop restaurant chain. The Kebab Shop has voluntarily paused sales of grilled beef kofta at all locations. 

Symptoms of STEC infection may include diarrhea (often bloody), vomiting and abdominal cramps. Symptoms usually start three to four days after a person is infected. Most people get better on their own within a week, but some people may develop severe diseases that require hospital care. Young children are at highest risk of getting hemolytic uremic syndrome (HUS), a severe complication that can lead to acute kidney failure.  

As of May 19, 2026, nine California residents have been infected with the outbreak strain of STEC O157:H7. Illness onset dates range from March 27 through April 30, 2026. Six illnesses are in children. Five individuals have been hospitalized, and two have developed HUS. No deaths have been reported. No individuals from other states are currently linked to this outbreak.  

Interviews with ill individuals indicate that grilled beef kofta served at The Kebab Shop is the likely outbreak source. The Kebab Shop is fully cooperating with public health officials and voluntarily paused sales of grilled beef kofta at all locations on May 18.  

The risk of exposure to this product is not ongoing at this time. While the investigation is ongoing, current information suggests the implicated beef product was distributed only to The Kebab Shop. CDPH and partner agencies continue to investigate to identify the cause of the outbreak, monitor for additional ill persons, and conduct product testing.  

William “Bill” Marler has been a food safety lawyer and advocate since the 1993 Jack-in-the-Box E. coli Outbreak which was chronicled in the book, “Poisoned” and in the recent Emmy Award winning Netflix documentary by the same name. Bill work has been profiled in the New Yorker, “A Bug in the System;” the Seattle Times, “30 years after the deadly E. coli outbreak, A Seattle attorney still fights for food safety;” the Washington Post, “He helped make burgers safer, Now he is fighting food poisoning again;” and several others. 

Dozens of times a year Bill speaks to industry and government throughout the United States, Canada, Europe, Africa, China and Australia on why it is important to prevent foodborne illnesses.  He is also a frequent commentator on food litigation and food safety on Marler Blog. Bill is also the publisher of Food Safety News.

E. coli:  Marler Clark, The Food Safety Law Firm, is the nation’s leading law firm representing victims of E. colioutbreaks and hemolytic uremic syndrome (HUS). The E. coli lawyers of Marler Clark have represented thousands of victims of E. coli and other foodborne illness infections and have recovered over $900 million for clients. Marler Clark is the only law firm in the nation with a practice focused exclusively on foodborne illness litigation.  Our E. coli lawyers have litigated E. coli and HUS cases stemming from outbreaks traced to ground beef, raw milk, lettuce, spinach, sprouts, and other food products.  The law firm has brought E. coli lawsuits against such companies as Jack in the Box, Dole, ConAgra, Cargill, and Jimmy John’s.  We have proudly represented such victims as Brianne KinerStephanie Smith and Linda Rivera.

If you or a family member became ill with an E. coli infection or HUS after consuming food and you’re interested in pursuing a legal claim, contact the Marler Clark E. coli attorneys for a free case evaluation.

Additional Resources:

The Minnesota Department of Health (MDH) has confirmed that two people in Minnesota became ill with Salmonella in April 2026 after consuming moringa capsules from the brand tnvitamins (lot 2793, expiration February 2028) purchased on Amazon. Neither person was hospitalized and both have recovered. MDH is warning people not to consume the tnvitamins brand of moringa leaf powder capsules.  

The two additional cases are an indication that a previously publicized multistate outbreak of Salmonella cases linked to dietary supplements is still ongoing. The two cases are associated with a newly identified product containing moringa leaf powder (the same ingredient in the products that caused the earlier cases).From November 2025 through February 2026, there had been 97 cases (seven in Minnesota), including 26 hospitalizations (five in Minnesota) in 32 states. There have been no deaths. MDH is working with the Minnesota Department of Agriculture, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and other states to investigate additional cases and to determine the extent of the problem.  There have been multiple recent Salmonella outbreaks associated with moringa leaf products, so health officials also advise people to consult their healthcare provider before using any Moringa products.Symptoms of Salmonella infection include diarrhea, abdominal pain and fever. Symptoms usually begin within 12 to 96 hours after exposure, but they can begin up to 2 weeks after exposure. Infections usually clear in 5 to 7 days, but about 28% of laboratory-confirmed cases require hospitalization.  Many Salmonella infections in otherwise healthy people do not require medical treatment. More serious infections occasionally occur. For those who seek medical care, most do not require antibiotics. However, antibiotic treatment may be warranted in some cases. If you’ve consumed the implicated product, become ill and are concerned about your health, consult your health care provider.Approximately 1,000 Salmonella infections are reported each year in Minnesota. More information on Salmonella and how to prevent it can be found on the MDH website at Salmonellosis (Salmonella).Further information can be found on the CDC and FDA websites:  

  • Salmonella Outbreak Linked to Moringa Leaf Powder | Salmonella Infection | CDCOutbreak Investigation of Salmonella: Moringa Leaf Powder (January 2026) | FDA 
  • A New Jersey cheese manufacturer today admitted to introducing adulterated queso fresco into interstate commerce, U.S. Attorney Robert Frazer announced.

    Abuelito Cheese Inc. a/k/a “El Abuelito Cheese,” a distributor of food products located in Paterson, New Jersey, pleaded guilty today before U.S. Magistrate Judge Cari Fais in Newark federal court to an Information charging the company with introducing adulterated food into interstate commerce.

    According to documents filed in this case and statements made in court:

    Abuelito manufactured food products, including soft, fresh cheese known as queso fresco, at its facility in New Jersey.  It distributed products, including queso fresco, within New Jersey and to neighboring states.  In February 2020, the U.S. Food and Drug Administration (FDA) conducted an inspection of Abuelito’s facility and alerted the company to the presence of non-pathogenic Listeria innocua and Listeria grayi in its facility. In June 2020, the FDA issued a Warning Letter to Abuelito, expressing serious concerns regarding alleged Food, Drug, and Cosmetic Act (FDCA) violations, and warning that conditions in the company’s facility were conducive for pathogenic Listeria monocytogenes. Abuelito’s products were ultimately linked to a February 2021 outbreak of listeriosis that resulted in at least 13 hospitalizations and one death across four states.

    A total of 13 people infected with the outbreak strain of Listeria monocytogenes were reported from 4 states (see map). Illnesses started on dates ranging from October 20, 2020, to March 17, 2021, with 12 illnesses occurring in 2021 (see timeline).

    Sick people ranged in age from less than 1 to 75 years, with a median age of 52. Twelve people were Hispanic, and seven people were female. Twelve people were hospitalized, and one death was reported from Maryland. Four people got sick during their pregnancy, resulting in two pregnancy losses and one premature birth; the fourth person remained pregnant after recovering.

    The offense carries a maximum potential penalty of 5 years of probation, and a fine of $500,000, or twice the gross gain or loss from the offense, whichever is greatest. Sentencing is scheduled for October 15, 2026.

    Individuals who believe they may have been impacted by the 2021 listeriosis outbreak associated with products sold as El Abuelito Cheese brand, distributed in Connecticut, New Jersey, Pennsylvania, and New York; Rio Grande Food Products brand, distributed in Virginia, North Carolina, and Maryland; and Rio Lindo brand, distributed in North Carolina and Maryland, may contact the Department of Justice’s Victim Witness Unit via the following toll free number: (888) 549-3945 or email:  VictimAssistance.fraud@usdoj.gov.

    U.S. Attorney Frazer credited special agents of the U.S. Food and Drug Administration’s Office of Criminal Investigations New York Field Office, under the direction of Special Agent in Charge Fernando McMillan, with the investigation leading to today’s guilty plea.

    The government is represented by Assistant U.S. Attorney Katherine M. Romano, Co-Chief of the General Crimes Unit, and Trial Attorney Lauren M. Elfner of the Department of Justice, Criminal Division, Fraud Section.